Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Barclays Adjusts Price Target on Merck & Company to $94 From $92, Maintains Overweight Rating

11/01/2021 | 09:51am EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
07:31aMerck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
07:25aMerck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
06:46aEuropean Commission Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Therapy for ..
BU
01/26Vaccinex Says Two Patients Showed Complete Response in Study of Combo Drug Treatment fo..
MT
01/25Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record Ma..
MT
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/25Merck Declares Divined for the First Quarter of 2022, Payable on April 7, 2022
CI
01/24Britain to Start Testing Merck & Co.'s COVID-19 Antiviral Drug
MT
01/24Egypt Clears Merck & Co.'s COVID-19 Pill For Emergency Use
MT
01/24EU Drug Regulator Reportedly Will Decide on Approval of Pfizer's COVID-19 Pill by End o..
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 434 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 081 M - -
P/E ratio 2021 16,9x
Yield 2021 3,30%
Capitalization 200 B 200 B -
EV / Sales 2021 4,48x
EV / Sales 2022 3,75x
Nbr of Employees 73 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 79,14 $
Average target price 92,09 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.3.26%199 903
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642